MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

A new device for meibomian gland debridement was safe and effective and demonstrated time and space benefits compared with conventional debridement and expression approaches, according to a study ...

In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are ...

Introduction Wound debridement is a critical medical procedure used to treat various types of wounds, including burns, <a target=_blank href= ...

corneal debridement During an interview with Alex Sigmund, DVM, DACVO, ahead of his lectures at Veterinary Meeting & Expo (VMX), he shared with dvm360 when veterinary professionals should be treating ...